It's not only due to smoking, as this survivor's story might help demonstrate—says one expert doctor: "All you need to be at ...

Non-small cell lung cancer accounts for nearly 85% of all lung cancer cases. Targeted immunotherapy is a common treatment, but it does not work for everyone. However, a new Moffitt Cancer Center ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that ...

Research shows that TIL therapy, an emerging type of immunotherapy, works in some patients with non-small cell lung cancer, ...

Non-small cell lung carcinoma (NSCLC), also called non-small cell lung cancer, is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope.

Mar. 11, 2024 — Scientists trained a machine-learning algorithm to predict accurately brain metastasis using biopsy samples from early-stage non-small cell lung cancer patients. It was also ...

Jacobio Pharma is making a play for the Chinese KRAS market, unveiling registrational lung cancer data that suggest its asset ...

The US FDA Accelerated Approval of sotorasib required the sponsor to conduct a randomized trial that compared the safety and efficacy of the approved dose with a lower dose. These results ...

A new meta-analysis on neoadjuvant therapy for non–small cell lung cancer (NSCLC) has unveiled findings indicating that neoadjuvant chemoimmunotherapy holds superiority over traditional ...

Statistics show that only 6.5% of eligible adults receive recommended lung cancer screenings. This low screening rate ...

On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

EU regulators have approved BeiGene's (BGNE) tislelizumab for the treatment of certain types of non-small cell lung cancer.